Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, cross-over study of Lisdexamfetamine dimesylate for the treatment of Attention Deficit Hyperactivity Disorder with anxiety disorder and depression comorbidity

Next Previous
Trial Profile

A double-blind, cross-over study of Lisdexamfetamine dimesylate for the treatment of Attention Deficit Hyperactivity Disorder with anxiety disorder and depression comorbidity

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use

Most Recent Events

  • 06 Nov 2018 New trial record
  • 09 Oct 2018 Results assessing the efficacy of Lisdexamfetamine in adult patients with ADHD with anxiety disorder and depression comorbidity, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top